HALO Diagnostics and Genomic Testing Cooperative Partner to Advance Early Cancer Detection and Precision Diagnostics
Press Releases

HALO Diagnostics and Genomic Testing Cooperative Partner to Advance Early Cancer Detection and Precision Diagnostics

SAN FRANCISCO (PRWEB) JUNE 14, 2022. HALO Diagnostics, a precision diagnostics leader, has joined forces with the Genomic Testing Cooperative (GTC) to offer innovative, personalized testing to its physician network and 1M+ patients served. This solution combines HALO Diagnostics’ clinical ensemble and image-guided therapies with GTC’s genomic profiling of a patient’s DNA / RNA using liquid biopsy and tissue samples. Together, the companies will help patients on every step of their unique healthcare journey – from detection and diagnosis to prognosis and treatment.

Read More »
vexas disease- Bone Marrow Aspirate NEJM
Article

Case Study: VEXAS Syndrome

Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of

Read More »
ASH22 Posters
Genomics

ASH22 Posters

GTC presented abstracts at ASH 2022 GTC’s posters from 2022 Convention of American Society of Hematology are now available to be downloaded. Please reach out

Read More »
GTC posters at ASH 2021 - Atlanta GA
Genomics

ASH21 Posters

In partnership with Anthology Diagnostics and Key Genomics, GTC presented four abstracts at ASH 2021 GTC’s posters from 2021 Convention of American Society of Hematology

Read More »